ID: ALA4442031

Max Phase: Preclinical

Molecular Formula: C22H18N2O4

Molecular Weight: 374.40

Molecule Type: Unknown

Representations

Canonical SMILES:  CCOC(=O)C(C)n1cc(-c2cccc3c2C(=O)c2ccccc2C3=O)cn1

Standard InChI:  InChI=1S/C22H18N2O4/c1-3-28-22(27)13(2)24-12-14(11-23-24)15-9-6-10-18-19(15)21(26)17-8-5-4-7-16(17)20(18)25/h4-13H,3H2,1-2H3

Standard InChI Key:  YFKGOBKLSOTNRJ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 374.40

Molecular Weight (Monoisotopic): 374.1267

AlogP: 3.45

#Rotatable Bonds: 4

Polar Surface Area: 78.26

Molecular Species: NEUTRAL

HBA: 6

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 1.97

CX LogP: 3.54

CX LogD: 3.54

Aromatic Rings: 3

Heavy Atoms: 28

QED Weighted: 0.51

Np Likeness Score: -0.44

References

1. Lee D, Pagire HS, Pagire SH, Bae EJ, Dighe M, Kim M, Lee KM, Jang YK, Jaladi AK, Jung KY, Yoo EK, Gim HE, Lee S, Choi WI, Chi YI, Song JS, Bae MA, Jeon YH, Lee GH, Liu KH, Lee T, Park S, Jeon JH, Lee IK, Ahn JH..  (2019)  Discovery of Novel Pyruvate Dehydrogenase Kinase 4 Inhibitors for Potential Oral Treatment of Metabolic Diseases.,  62  (2): [PMID:30623649] [10.1021/acs.jmedchem.8b01168]

Source

Source(1):

• Scientific Literature